{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:44:30Z","timestamp":1794008670058,"version":"4.8.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital","award":["CY2021-MS-A12"],"award-info":[{"award-number":["CY2021-MS-A12"]}]},{"name":"Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital","award":["CY2021-MS-A12"],"award-info":[{"award-number":["CY2021-MS-A12"]}]},{"name":"Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital","award":["CY2021-MS-A12"],"award-info":[{"award-number":["CY2021-MS-A12"]}]},{"name":"Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital","award":["CY2021-MS-A12"],"award-info":[{"award-number":["CY2021-MS-A12"]}]},{"name":"Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital","award":["CY2021-MS-A12"],"award-info":[{"award-number":["CY2021-MS-A12"]}]},{"name":"Investigation of the Effects and Mechanisms of HTRA1 on Bladder Tumors Through Combined Non-invasive Urinary Metabolomics","award":["22YF7FA090"],"award-info":[{"award-number":["22YF7FA090"]}]},{"name":"Investigation of the Effects and Mechanisms of HTRA1 on Bladder Tumors Through Combined Non-invasive Urinary Metabolomics","award":["22YF7FA090"],"award-info":[{"award-number":["22YF7FA090"]}]},{"name":"Investigation of the Effects and Mechanisms of HTRA1 on Bladder Tumors Through Combined Non-invasive Urinary Metabolomics","award":["22YF7FA090"],"award-info":[{"award-number":["22YF7FA090"]}]},{"name":"Investigation of the Effects and Mechanisms of HTRA1 on Bladder Tumors Through Combined Non-invasive Urinary Metabolomics","award":["22YF7FA090"],"award-info":[{"award-number":["22YF7FA090"]}]},{"name":"Investigation of the Effects and Mechanisms of HTRA1 on Bladder Tumors Through Combined Non-invasive Urinary Metabolomics","award":["22YF7FA090"],"award-info":[{"award-number":["22YF7FA090"]}]},{"name":"Exploring the Accuracy and Mechanisms of Non-Invasive Urinary HTRA1 Molecular Detection in Bladder Cancer Diagnosis","award":["23JRRA1006"],"award-info":[{"award-number":["23JRRA1006"]}]},{"name":"Exploring the Accuracy and Mechanisms of Non-Invasive Urinary HTRA1 Molecular Detection in Bladder Cancer Diagnosis","award":["23JRRA1006"],"award-info":[{"award-number":["23JRRA1006"]}]},{"name":"Exploring the Accuracy and Mechanisms of Non-Invasive Urinary HTRA1 Molecular Detection in Bladder Cancer Diagnosis","award":["23JRRA1006"],"award-info":[{"award-number":["23JRRA1006"]}]},{"name":"Exploring the Accuracy and Mechanisms of Non-Invasive Urinary HTRA1 Molecular Detection in Bladder Cancer Diagnosis","award":["23JRRA1006"],"award-info":[{"award-number":["23JRRA1006"]}]},{"name":"Exploring the Accuracy and Mechanisms of Non-Invasive Urinary HTRA1 Molecular Detection in Bladder Cancer Diagnosis","award":["23JRRA1006"],"award-info":[{"award-number":["23JRRA1006"]}]},{"name":"Multimodal Urinary Analysis for the Identification of Bladder Tumor Biomarkers and Investigation into the Molecular Mechanisms of HTRA1","award":["2023-4-34"],"award-info":[{"award-number":["2023-4-34"]}]},{"name":"Multimodal Urinary Analysis for the Identification of Bladder Tumor Biomarkers and Investigation into the Molecular Mechanisms of HTRA1","award":["2023-4-34"],"award-info":[{"award-number":["2023-4-34"]}]},{"name":"Multimodal Urinary Analysis for the Identification of Bladder Tumor Biomarkers and Investigation into the Molecular Mechanisms of HTRA1","award":["2023-4-34"],"award-info":[{"award-number":["2023-4-34"]}]},{"name":"Multimodal Urinary Analysis for the Identification of Bladder Tumor Biomarkers and Investigation into the Molecular Mechanisms of HTRA1","award":["2023-4-34"],"award-info":[{"award-number":["2023-4-34"]}]},{"name":"Multimodal Urinary Analysis for the Identification of Bladder Tumor Biomarkers and Investigation into the Molecular Mechanisms of HTRA1","award":["2023-4-34"],"award-info":[{"award-number":["2023-4-34"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82160146"],"award-info":[{"award-number":["No. 82160146"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82160146"],"award-info":[{"award-number":["No. 82160146"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89217-4","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T11:21:46Z","timestamp":1739013706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mechanistic insights into PROS1 inhibition of bladder cancer progression and angiogenesis via the AKT\/GSK3\u03b2\/\u03b2-catenin pathway"],"prefix":"10.1038","volume":"15","author":[{"given":"Xin-peng","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-long","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-yun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan-jie","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"89217_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"Cancer J. Clin."},{"key":"89217_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. Cancer J. Clin. 70, 404\u2013423. https:\/\/doi.org\/10.3322\/caac.21631 (2020).","journal-title":"Cancer J. Clin."},{"key":"89217_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk, M. et al. European Association of Urology Guidelines on non-muscle-invasive bladder Cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 81, 75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010 (2022).","journal-title":"Eur. Urol."},{"key":"89217_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.eururo.2012.05.008","volume":"62","author":"V Soukup","year":"2012","unstructured":"Soukup, V. et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur. Urol. 62, 290\u2013302. https:\/\/doi.org\/10.1016\/j.eururo.2012.05.008 (2012).","journal-title":"Eur. Urol."},{"key":"89217_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.eururo.2011.11.011","volume":"61","author":"S Holm\u00e4ng","year":"2012","unstructured":"Holm\u00e4ng, S. & Str\u00f6ck, V. Should follow-up cystoscopy in bacillus Calmette-Gu\u00e9rin-treated patients continue after five tumour-free years? Eur. Urol. 61, 503\u2013507. https:\/\/doi.org\/10.1016\/j.eururo.2011.11.011 (2012).","journal-title":"Eur. Urol."},{"key":"89217_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes, J. et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder Cancer: Summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016 (2024).","journal-title":"Eur. Urol."},{"key":"89217_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang, S. S. et al. Treatment of non-metastatic muscle-invasive bladder Cancer: AUA\/ASCO\/ASTRO\/SUO Guideline. J. Urol. 198, 552\u2013559. https:\/\/doi.org\/10.1016\/j.juro.2017.04.086 (2017).","journal-title":"J. Urol."},{"key":"89217_CR8","doi-asserted-by":"publisher","unstructured":"Neoadjuvant chemotherapy in invasive. bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202\u2013205. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.006 (2005).","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"89217_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin, M. et al. Neoadjuvant chemotherapy for muscle-invasive bladder Cancer: a systematic review and two-step Meta-analysis. Oncologist 21, 708\u2013715. https:\/\/doi.org\/10.1634\/theOncologist.2015-0440 (2016).","journal-title":"Oncologist"},{"key":"89217_CR10","doi-asserted-by":"publisher","first-page":"630773","DOI":"10.3389\/fimmu.2021.630773","volume":"12","author":"A Lin","year":"2021","unstructured":"Lin, A., Qiu, Z., Zhang, J. & Luo, P. Effect of NCOR1 mutations on Immune Microenvironment and Efficacy of Immune checkpoint inhibitors in patient with bladder Cancer. Front. Immunol. 12, 630773. https:\/\/doi.org\/10.3389\/fimmu.2021.630773 (2021).","journal-title":"Front. Immunol."},{"key":"89217_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer. 118, 9\u201316. https:\/\/doi.org\/10.1038\/bjc.2017.434 (2018).","journal-title":"Br. J. Cancer"},{"key":"89217_CR12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nature04478","volume":"438","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932\u2013936. https:\/\/doi.org\/10.1038\/nature04478 (2005).","journal-title":"Nature"},{"key":"89217_CR13","doi-asserted-by":"publisher","unstructured":"Oshi, M. et al. Intra-tumoral Angiogenesis is Associated with inflammation, Immune reaction and metastatic recurrence in breast Cancer. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21186708 (2020).","DOI":"10.3390\/ijms21186708"},{"issue":"Suppl 2","key":"89217_CR14","first-page":"S134","volume":"6","author":"IJ Fidler","year":"2000","unstructured":"Fidler, I. J. Angiogenesis and cancer metastasis. Cancer J. (Sudbury Mass). 6 (Suppl 2), S134\u2013141 (2000).","journal-title":"Cancer J. (Sudbury Mass)"},{"key":"89217_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejmech.2017.06.030","volume":"142","author":"A Markowska","year":"2017","unstructured":"Markowska, A., Sajdak, S., Markowska, J. & Huczy\u0144ski, A. Angiogenesis and cancer stem cells: new perspectives on therapy of ovarian cancer. Eur. J. Med. Chem. 142, 87\u201394. https:\/\/doi.org\/10.1016\/j.ejmech.2017.06.030 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"89217_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canlet.2021.09.036","volume":"523","author":"X Li","year":"2021","unstructured":"Li, X. et al. Secretory autophagy-induced bladder tumour-derived extracellular vesicle secretion promotes angiogenesis by activating the TPX2-mediated phosphorylation of the AURKA-PI3K-AKT axis. Cancer Lett. 523, 10\u201328. https:\/\/doi.org\/10.1016\/j.canlet.2021.09.036 (2021).","journal-title":"Cancer Lett."},{"key":"89217_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10120-015-0537-5","volume":"19","author":"G Roviello","year":"2016","unstructured":"Roviello, G. et al. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric cancer: Official J. Int. Gastric Cancer Association Japanese Gastric Cancer Association. 19, 31\u201341. https:\/\/doi.org\/10.1007\/s10120-015-0537-5 (2016).","journal-title":"Gastric cancer: Official J. Int. Gastric Cancer Association Japanese Gastric Cancer Association"},{"key":"89217_CR18","doi-asserted-by":"publisher","unstructured":"Shao, F. et al. Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer. Urol. Oncol. 41 https:\/\/doi.org\/10.1016\/j.urolonc.2023.07.006 (2023). 433.e439-433.e418.","DOI":"10.1016\/j.urolonc.2023.07.006"},{"key":"89217_CR19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1021\/bi00623a022","volume":"16","author":"RG Di Scipio","year":"1977","unstructured":"Di Scipio, R. G., Hermodson, M. A., Yates, S. G. & Davie, E. W. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 16, 698\u2013706. https:\/\/doi.org\/10.1021\/bi00623a022 (1977).","journal-title":"Biochemistry"},{"key":"89217_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nri2303","volume":"8","author":"G Lemke","year":"2008","unstructured":"Lemke, G. & Rothlin, C. V. Immunobiology of the TAM receptors. Nat. Rev. Immunol. 8, 327\u2013336. https:\/\/doi.org\/10.1038\/nri2303 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"89217_CR21","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3892\/ijo.2016.3755","volume":"49","author":"MF Che Mat","year":"2016","unstructured":"Che Mat, M. F. et al. Silencing of PROS1 induces apoptosis and inhibits migration and invasion of glioblastoma multiforme cells. Int. J. Oncol. 49, 2359\u20132366. https:\/\/doi.org\/10.3892\/ijo.2016.3755 (2016).","journal-title":"Int. J. Oncol."},{"key":"89217_CR22","doi-asserted-by":"publisher","first-page":"13986","DOI":"10.18632\/oncotarget.14753","volume":"8","author":"G Abboud-Jarrous","year":"2017","unstructured":"Abboud-Jarrous, G. et al. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL. Oncotarget 8, 13986\u201314002. https:\/\/doi.org\/10.18632\/oncotarget.14753 (2017).","journal-title":"Oncotarget"},{"key":"89217_CR23","doi-asserted-by":"publisher","first-page":"34019","DOI":"10.1074\/jbc.M112.384438","volume":"287","author":"P Saraon","year":"2012","unstructured":"Saraon, P. et al. Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer. J. Biol. Chem. 287, 34019\u201334031. https:\/\/doi.org\/10.1074\/jbc.M112.384438 (2012).","journal-title":"J. Biol. Chem."},{"key":"89217_CR24","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.thromres.2009.09.011","volume":"125","author":"E Sierko","year":"2010","unstructured":"Sierko, E., Wojtukiewicz, M. Z., Zawadzki, R., Zimnoch, L. & Kisiel, W. Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer. Thromb. Res. 125, e71\u201375. https:\/\/doi.org\/10.1016\/j.thromres.2009.09.011 (2010).","journal-title":"Thromb. Res."},{"key":"89217_CR25","doi-asserted-by":"publisher","first-page":"110918","DOI":"10.1016\/j.cellsig.2023.110918","volume":"112","author":"T He","year":"2023","unstructured":"He, T. et al. PROS1, a clinical prognostic biomarker and tumor suppressor, is associated with immune cell infiltration in breast cancer: a bioinformatics analysis combined with experimental verification. Cell. Signal. 112, 110918. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110918 (2023).","journal-title":"Cell. Signal."},{"key":"89217_CR26","doi-asserted-by":"publisher","unstructured":"Maimon, A. et al. Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10. J. Clin. Investig. 131 https:\/\/doi.org\/10.1172\/jci126089 (2021).","DOI":"10.1172\/jci126089"},{"key":"89217_CR27","doi-asserted-by":"publisher","first-page":"843077","DOI":"10.3389\/fimmu.2022.843077","volume":"13","author":"X Qing","year":"2022","unstructured":"Qing, X. et al. Molecular characteristics, clinical significance, and Cancer Immune interactions of Angiogenesis-Associated genes in gastric Cancer. Front. Immunol. 13, 843077. https:\/\/doi.org\/10.3389\/fimmu.2022.843077 (2022).","journal-title":"Front. Immunol."},{"key":"89217_CR28","doi-asserted-by":"publisher","unstructured":"Wan, S. et al. Exploring potential targets of HPV&BC based on network pharmacology and urine proteomics. J. Pharm. Biomed. Anal. 236 https:\/\/doi.org\/10.1016\/j.jpba.2023.115694 (2023).","DOI":"10.1016\/j.jpba.2023.115694"},{"key":"89217_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"89217_CR30","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Science: Publication Protein Soc. 28, 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Science: Publication Protein Soc."},{"key":"89217_CR31","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013d592. https:\/\/doi.org\/10.1093\/nar\/gkac963 (2023).","journal-title":"Nucleic Acids Res."},{"key":"89217_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249\u2013257. https:\/\/doi.org\/10.1038\/35025220 (2000).","journal-title":"Nature"},{"key":"89217_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3892\/ol.2021.13126","volume":"23","author":"HL Li","year":"2022","unstructured":"Li, H. L. et al. Isoliensinine induces cervical cancer cell cycle arrest and apoptosis by inhibiting the AKT\/GSK3\u03b1 pathway. Oncol. Lett. 23, 8. https:\/\/doi.org\/10.3892\/ol.2021.13126 (2022).","journal-title":"Oncol. Lett."},{"key":"89217_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41419-021-03504-2","volume":"12","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. GLI1 reduces drug sensitivity by regulating cell cycle through PI3K\/AKT\/GSK3\/CDK pathway in acute myeloid leukemia. Cell Death Dis. 12, 231. https:\/\/doi.org\/10.1038\/s41419-021-03504-2 (2021).","journal-title":"Cell Death Dis."},{"key":"89217_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12640-020-00210-3","volume":"38","author":"H Ji","year":"2020","unstructured":"Ji, H. et al. Pyrroloquinoline quinine and LY294002 changed cell cycle and apoptosis by regulating PI3K-AKT-GSK3\u03b2 pathway in SH-SY5Y cells. Neurotox. Res. 38, 266\u2013273. https:\/\/doi.org\/10.1007\/s12640-020-00210-3 (2020).","journal-title":"Neurotox. Res."},{"key":"89217_CR36","doi-asserted-by":"publisher","unstructured":"Shi, Y. et al. Ginsenoside Rg1 alleviates podocyte EMT passage by regulating AKT\/GSK3 \u03b2\/\u03b2-Catenin pathway by restoring autophagic activity. Evid.-Based Complem. Altern. Med.  2020, 1903627. https:\/\/doi.org\/10.1155\/2020\/1903627 (2020).","DOI":"10.1155\/2020\/1903627"},{"key":"89217_CR37","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s11033-021-06173-8","volume":"48","author":"Z Ozman","year":"2021","unstructured":"Ozman, Z. et al. Regulation of valproic acid induced EMT by AKT\/GSK3\u03b2\/\u03b2-catenin signaling pathway in triple negative breast cancer. Mol. Biol. Rep. 48, 1335\u20131343. https:\/\/doi.org\/10.1007\/s11033-021-06173-8 (2021).","journal-title":"Mol. Biol. Rep."},{"key":"89217_CR38","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11912-023-01421-5","volume":"25","author":"G Elayat","year":"2023","unstructured":"Elayat, G., Punev, I. & Selim, A. An overview of angiogenesis in bladder Cancer. Curr. Oncol. Rep. 25, 709\u2013728. https:\/\/doi.org\/10.1007\/s11912-023-01421-5 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"89217_CR39","doi-asserted-by":"publisher","unstructured":"Lin, Y. H. et al. The reduction of PSMB4 in T24 and J82 bladder Cancer cells inhibits the Angiogenesis and Migration of endothelial cells. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms25105559 (2024).","DOI":"10.3390\/ijms25105559"},{"key":"89217_CR40","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1159\/000491536","volume":"47","author":"T Hou","year":"2018","unstructured":"Hou, T. et al. Leupaxin promotes bladder Cancer Proliferation, Metastasis, and Angiogenesis through the PI3K\/AKT pathway. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 47, 2250\u20132260. https:\/\/doi.org\/10.1159\/000491536 (2018).","journal-title":"Cell. Physiol. Biochemistry: Int. J. Experimental Cell. Physiol. Biochem. Pharmacol."},{"key":"89217_CR41","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.3892\/or.2020.7689","volume":"44","author":"VS Pilli","year":"2020","unstructured":"Pilli, V. S., Datta, A., Dorsey, A., Liu, B. & Majumder, R. Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancreatic cancer cell survival and proliferation. Oncol. Rep. 44, 1322\u20131332. https:\/\/doi.org\/10.3892\/or.2020.7689 (2020).","journal-title":"Oncol. Rep."},{"key":"89217_CR42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12957-022-02801-0","volume":"20","author":"M Wei","year":"2022","unstructured":"Wei, M., Wang, Y., Liu, Y., Li, D. & He, X. AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour. World J. Surg. Oncol. 20, 334. https:\/\/doi.org\/10.1186\/s12957-022-02801-0 (2022).","journal-title":"World J. Surg. Oncol."},{"key":"89217_CR43","doi-asserted-by":"publisher","unstructured":"Wang, J. et al. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma. Front. Immunol. 13 https:\/\/doi.org\/10.3389\/fimmu.2022.1052692 (2022).","DOI":"10.3389\/fimmu.2022.1052692"},{"key":"89217_CR44","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.26355\/eurrev_201806_15270","volume":"22","author":"JJ Wang","year":"2018","unstructured":"Wang, J. J., Lei, K. F. & Han, F. Tumor microenvironment: recent advances in various cancer treatments. Eur. Rev. Med. Pharmacol. Sci. 22, 3855\u20133864. https:\/\/doi.org\/10.26355\/eurrev_201806_15270 (2018).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"89217_CR45","doi-asserted-by":"publisher","unstructured":"Martori, C. et al. Macrophages as a therapeutic target in metastatic prostate Cancer: A way to overcome immunotherapy resistance? Cancers 14 https:\/\/doi.org\/10.3390\/cancers14020440 (2022).","DOI":"10.3390\/cancers14020440"},{"key":"89217_CR46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka, A. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Res. 27, 109\u2013118. https:\/\/doi.org\/10.1038\/cr.2016.151 (2017).","journal-title":"Cell Res."},{"key":"89217_CR47","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","volume":"11","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F., Meylan, M., de Reyni\u00e8s, A., Saut\u00e8s-Fridman, C. & Fridman, W. H. The Tumor Microenvironment in the response to Immune Checkpoint Blockade therapies. Front. Immunol. 11, 784. https:\/\/doi.org\/10.3389\/fimmu.2020.00784 (2020).","journal-title":"Front. Immunol."},{"key":"89217_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11538-022-01095-3","volume":"84","author":"L Almeida","year":"2022","unstructured":"Almeida, L., Audebert, C., Leschiera, E. & Lorenzi, T. A. Hybrid discrete-continuum Modelling Approach to explore the impact of T-Cell infiltration on Anti-tumour Immune Response. Bull. Math. Biol. 84, 141. https:\/\/doi.org\/10.1007\/s11538-022-01095-3 (2022).","journal-title":"Bull. Math. Biol."},{"key":"89217_CR49","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-023-03949-3","volume":"21","author":"FJ Koll","year":"2023","unstructured":"Koll, F. J. et al. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis. J. Translational Med. 21, 124. https:\/\/doi.org\/10.1186\/s12967-023-03949-3 (2023).","journal-title":"J. Translational Med."},{"key":"89217_CR50","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701. https:\/\/doi.org\/10.1038\/s41586-019-1671-8 (2019).","journal-title":"Nature"},{"key":"89217_CR51","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer cell. 39, 154\u2013173. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.001 (2021).","journal-title":"Cancer cell."},{"key":"89217_CR52","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1914919","volume":"382","author":"YR Lee","year":"2020","unstructured":"Lee, Y. R. et al. WWP1 gain-of-function inactivation of PTEN in Cancer Predisposition. N. Engl. J. Med. 382, 2103\u20132116. https:\/\/doi.org\/10.1056\/NEJMoa1914919 (2020).","journal-title":"N. Engl. J. Med."},{"key":"89217_CR53","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/s41418-019-0466-7","volume":"27","author":"Y Guo","year":"2020","unstructured":"Guo, Y. et al. GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer. Cell Death Differ. 27, 1862\u20131877. https:\/\/doi.org\/10.1038\/s41418-019-0466-7 (2020).","journal-title":"Cell Death Differ."},{"key":"89217_CR54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/mph.0000000000000329","volume":"37","author":"D King","year":"2015","unstructured":"King, D., Yeomanson, D. & E Bryant, H. PI3King the lock: targeting the PI3K\/Akt\/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J. Pediatr. Hematol. Oncol. 37, 245\u2013251. https:\/\/doi.org\/10.1097\/mph.0000000000000329 (2015).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"89217_CR55","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013339. https:\/\/doi.org\/10.1038\/nature12634 (2013).","journal-title":"Nature"},{"key":"89217_CR56","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.atherosclerosis.2010.07.061","volume":"213","author":"K Tsoyi","year":"2010","unstructured":"Tsoyi, K. et al. PTEN differentially regulates expressions of ICAM-1 and VCAM-1 through PI3K\/Akt\/GSK-3\u03b2\/GATA-6 signaling pathways in TNF-\u03b1-activated human endothelial cells. Atherosclerosis 213, 115\u2013121. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.07.061 (2010).","journal-title":"Atherosclerosis"},{"key":"89217_CR57","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1124\/jpet.105.096826","volume":"317","author":"W Yan","year":"2006","unstructured":"Yan, W. & Tai, H. H. Glycogen synthase kinase-3 phosphorylation, T-cell factor signaling activation, and cell morphology change following stimulation of thromboxane receptor alpha. J. Pharmacol. Exp. Ther. 317, 267\u2013274. https:\/\/doi.org\/10.1124\/jpet.105.096826 (2006).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"89217_CR58","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3892\/or.2018.6195","volume":"39","author":"X Shi","year":"2018","unstructured":"Shi, X. et al. Knockdown of hnRNP A2\/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K\/AKT signaling pathway. Oncol. Rep. 39, 939\u2013950. https:\/\/doi.org\/10.3892\/or.2018.6195 (2018).","journal-title":"Oncol. Rep."},{"key":"89217_CR59","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning, B. D. & Cantley, L. C. AKT\/PKB signaling: navigating downstream. Cell 129, 1261\u20131274. https:\/\/doi.org\/10.1016\/j.cell.2007.06.009 (2007).","journal-title":"Cell"},{"key":"89217_CR60","doi-asserted-by":"publisher","unstructured":"Shen, Q. et al. MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K\/Akt signaling. Signal. Transduct. Target. The. 7 https:\/\/doi.org\/10.1038\/s41392-022-00945-9 (2022).","DOI":"10.1038\/s41392-022-00945-9"},{"key":"89217_CR61","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41420-024-02008-0","volume":"10","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. IL-1\u03b2 promotes esophageal squamous cell carcinoma growth and metastasis through FOXO3A by activating the PI3K\/AKT pathway. Cell. Death Discovery. 10, 238. https:\/\/doi.org\/10.1038\/s41420-024-02008-0 (2024).","journal-title":"Cell. Death Discovery"},{"key":"89217_CR62","doi-asserted-by":"publisher","unstructured":"Li, S. et al. Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer. Cell. Mol. Biol. Lett. 28 https:\/\/doi.org\/10.1186\/s11658-023-00442-z (2023).","DOI":"10.1186\/s11658-023-00442-z"},{"key":"89217_CR63","doi-asserted-by":"publisher","unstructured":"Ferro, M. et al. Liquid biopsy biomarkers in urine: a Route towards Molecular diagnosis and personalized medicine of bladder Cancer. J. Pers. Med. 11 https:\/\/doi.org\/10.3390\/jpm11030237 (2021).","DOI":"10.3390\/jpm11030237"},{"key":"89217_CR64","doi-asserted-by":"publisher","unstructured":"Lone, S. N. et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol. Cancer. 21 https:\/\/doi.org\/10.1186\/s12943-022-01543-7 (2022).","DOI":"10.1186\/s12943-022-01543-7"},{"key":"89217_CR65","doi-asserted-by":"publisher","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224. https:\/\/doi.org\/10.1126\/scitranslmed.3007094 (2014).","journal-title":"Sci. Transl. Med."},{"key":"89217_CR66","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/clinchem\/hvac218","volume":"69","author":"MA Papadimitriou","year":"2023","unstructured":"Papadimitriou, M. A. et al. Preoperative cell-free DNA (cfDNA) in muscle-invasive bladder Cancer Treatment Outcome. Clin. Chem. 69, 399\u2013410. https:\/\/doi.org\/10.1093\/clinchem\/hvac218 (2023).","journal-title":"Clin. Chem."},{"key":"89217_CR67","doi-asserted-by":"publisher","first-page":"e2300414","DOI":"10.1200\/po.23.00414","volume":"8","author":"KM Pilala","year":"2024","unstructured":"Pilala, K. M. et al. MIR145 core promoter methylation in pretreatment cell-free DNA: a Liquid Biopsy Tool for muscle-invasive bladder Cancer Treatment Outcome. JCO Precision Oncol. 8, e2300414. https:\/\/doi.org\/10.1200\/po.23.00414 (2024).","journal-title":"JCO Precision Oncol."},{"key":"89217_CR68","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41585-022-00564-7","volume":"19","author":"T Thomas","year":"2022","unstructured":"Thomas, T. Bladder EpiCheck for NMIBC. Nat. Rev. Urol. 19, 67. https:\/\/doi.org\/10.1038\/s41585-022-00564-7 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"89217_CR69","doi-asserted-by":"publisher","first-page":"e0245264","DOI":"10.1371\/journal.pone.0245264","volume":"16","author":"A Sabah","year":"2021","unstructured":"Sabah, A., Tiun, S., Sani, N. S., Ayob, M. & Taha, A. Y. Enhancing web search result clustering model based on multiview multirepresentation consensus cluster ensemble (mmcc) approach. PloS One. 16, e0245264. https:\/\/doi.org\/10.1371\/journal.pone.0245264 (2021).","journal-title":"PloS One"},{"key":"89217_CR70","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/omi.2009.0083","volume":"14","author":"M Seiler","year":"2010","unstructured":"Seiler, M., Huang, C. C., Szalma, S. & Bhanot, G. ConsensusCluster: a software tool for unsupervised cluster discovery in numerical data. Omics: J. Integr. Biology. 14, 109\u2013113. https:\/\/doi.org\/10.1089\/omi.2009.0083 (2010).","journal-title":"Omics: J. Integr. Biology"},{"key":"89217_CR71","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.otohns.2010.05.007","volume":"143","author":"JT Rich","year":"2010","unstructured":"Rich, J. T. et al. A practical guide to understanding Kaplan-Meier curves. Otolaryngoll. Head Neck Surg. 143, 331\u2013336. https:\/\/doi.org\/10.1016\/j.otohns.2010.05.007 (2010).","journal-title":"Otolaryngology\u2013head neck Surgery: Official J. Am. Acad. Otolaryngology-Head Neck Surg."},{"key":"89217_CR72","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013w514. https:\/\/doi.org\/10.1093\/nar\/gkaa407 (2020).","journal-title":"Nucleic Acids Res."},{"key":"89217_CR73","doi-asserted-by":"publisher","unstructured":"Rody, A. et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 11, R15. https:\/\/doi.org\/10.1186\/bcr2234 (2009).","DOI":"10.1186\/bcr2234"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89217-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89217-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89217-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T11:21:59Z","timestamp":1739013719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89217-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89217"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89217-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We confirmed that all experiments in this study were performed in accordance with the relevant guidelines and regulations. All the procedure of the study is followed by the ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"4748"}}